-
Lexicon Pharmaceuticals Advances Pilavapadin Towards Late-Stage Trials for Diabetic Neuropathic Pain
NASDAQ: $LXRX Lexicon Pharmaceuticals recently shared significant news regarding its investigational drug, pilavapadin, marking a crucial step forward in the potential treatment landscape for diabetic peripheral neuropathic pain (DPNP). The company announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). Understanding the Significance of the FDA Meeting…
-
Legend Biotech Announces Key Data Presentation for CARVYKTI at 2026 Tandem Meetings
NASDAQ: $LEGN Advancing the Frontier: Legend Biotech Prepares for Major Data Showcase Legend Biotech Corporation (NASDAQ: $LEGN) has recently announced an important upcoming event that underscores their commitment to innovative cancer therapies. According to a press release dated January 21, 2026, the company will be presenting new data concerning its groundbreaking therapy, CARVYKTI® (ciltacabtagene autoleucel),…
-
Progress Report: Aligos Therapeutics’ SUPREME Trial in Hepatitis B
NASDAQ: $ALGS Aligos Therapeutics recently issued an update concerning the progress of its Phase 2b SUPREME study, a significant development in the ongoing effort to find effective treatments for chronic Hepatitis B virus (HBV) infection. For those following pharmaceutical advancements in virology, this announcement provides valuable insight into the trajectory of their lead candidate. The…
-
Groundbreaking Clinical Results for Intranasal Foralumab Published by Tiziana Life Sciences
NASDAQ: $TLSA Tiziana Life Sciences plc recently announced a significant milestone in their ongoing research and development efforts: the peer-reviewed publication of clinical study results concerning their lead product candidate, intranasal Foralumab. This publication, detailed in a press release issued on January 20, 2026, marks a crucial step forward in validating the potential of this…
-
Nxera Pharma Announces Promising Phase 3 Trial Results for Daridorexant in South Korea
The pharmaceutical landscape received exciting news recently following the announcement from Nxera Pharma regarding the positive outcomes of its Phase 3 clinical trial for Daridorexant, conducted specifically in South Korea. This development marks a significant step forward in making a potentially transformative treatment option available to patients suffering from insomnia in the region. Understanding the…
-
A Significant Step Forward: First U.S. Patient Enrolled in BiPASS Phase 3 Study for Prostate Cancer Diagnosis
NASDAQ: $TLX Today marks an important milestone in the ongoing effort to improve the diagnosis and management of prostate cancer. We are excited to share news regarding the initiation of dosing for the first U.S. patient in the pivotal BiPASS Phase 3 clinical trial. This study focuses on assessing the performance of a novel diagnostic…
-
Exciting Progress: Corvus Pharmaceuticals Poised to Share Promising Data on Soquelitinib for Atopic Dermatitis
NASDAQ: $CRVS Pharmaceutical research is a journey of meticulous steps, and today, the spotlight shines brightly on Corvus Pharmaceuticals as they prepare to share significant updates from their ongoing clinical investigations. Specifically, the market and the patient community are eagerly anticipating the forthcoming announcement regarding the results from Cohort 4 of the placebo-controlled Phase 1…
-
A New Dawn for DLBCL Treatment? Analyzing Incyte’s Promising Tafasitamab Data
NASDAQ: $INCY The landscape of hematologic oncology is constantly evolving, and recent news from Incyte has sent ripples of excitement through the medical community. Specifically, the announcement of positive topline results from a pivotal study of tafasitamab (marketed as Monjuvi/Minjuvi) as a first-line treatment for Diffuse Large B-Cell Lymphoma (DLBCL) signals a potentially significant step…
-
Regenxbio Charts Course for 2026: A Deep Dive into Duchenne Gene Therapy Milestones and Promising Long-Term Data
NASDAQ: $RGNX Biotechnology is often a story of patience, rigorous science, and the relentless pursuit of life-changing therapies. Nowhere is this more evident than in the field of gene therapy, especially concerning devastating conditions like Duchenne Muscular Dystrophy (DMD). Regenxbio, Inc. (NASDAQ: $RGNX) has recently provided a significant update, illuminating a clear roadmap toward crucial…
-
Decoding Tenax Therapeutics’ Latest Update: What the Blinded Sample Size Assessment Really Means
NASDAQ: $TENX Unpacking the Latest News from Tenax Therapeutics The world of clinical trials is often shrouded in complexity, full of acronyms and technical jargon that can leave even seasoned investors scratching their heads. Recently, a press release from Tenax Therapeutics ($TENX) caught the attention of the biotech community, specifically concerning the results of a…
-
NRx Pharmaceuticals Achieves Debt-Free Status Ahead of Drug Approvals
NASDAQ: $NRXP Summary of the Article/Press Release On December 18, 2025, NRx Pharmaceuticals, Inc. (Nasdaq: $NRXP), a clinical-stage biopharmaceutical company focused on treatments for central nervous system disorders like suicidal depression and PTSD, announced that it has fully eliminated its balance sheet debt. CEO Dr. Jonathan Javitt thanked Anson Funds for their support during tough…
-
Sarepta Therapeutics Continues Phase 3 Study of ELEVIDYS Gene Therapy in Duchenne
NASDAQ: $SRPT Sarepta Therapeutics (NasdaqGS: $SRPT) is at the forefront of innovation in the treatment of Duchenne Muscular Dystrophy (DMD) with its groundbreaking gene therapy, ELEVIDYS. As a rare, progressive genetic disorder, DMD significantly impairs muscle function and can lead to severe health complications. In an effort to provide new hope to affected individuals and…
-
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors
NASDAQ: $IDYA IDEAYA Biosciences’ recent exclusive license agreement with Hengrui Pharma for SHR-4849 marks a significant milestone in the field of oncology therapeutics. This partnership brings forth a promising novel Phase 1 DLL3 Topo-I-Payload Antibody-Drug Conjugate (ADC) targeting Small Cell Lung Cancer (SCLC) and Neuroendocrine Tumors (NET). The collaboration between these two renowned pharmaceutical companies…
-
Presentation of topline long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial highlighting new findings from the ATTENTION-AD study evaluating potential benefit of oral once daily blarcamesine (ANAVEX®2-73) in early Alzheimer’s disease.
NASDAQ: $AVXL The presentation of topline long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial marks a significant milestone in the field of Alzheimer’s disease research. This article delves into the latest findings from the ATTENTION-AD trial, shedding light on the efficacy and safety of the investigational treatment over an extended period. With a…
-
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
NASDAQ: $CGEM 1. Introduction to CLN-617: A Novel Fusion Protein The field of oncology research continues to evolve with the aim of developing innovative and effective therapies to combat cancer. In this regard, Cullinan Oncology has recently announced the initiation of a Phase 1 clinical trial to evaluate the potential of CLN-617, a novel fusion…
-
Kura Oncology | Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial
NASDAQ: $KURA SAN DIEGO, Dec. 08, 2023 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (NASDAQ: $KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and The Leukemia & Lymphoma Society (LLS), the largest private funder of blood cancer research, today announced a clinical collaboration to evaluate Kura’s…
-
Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine
NASDAQ: ANIX 1. Introduction to Anixa Biosciences and Cleveland Clinic collaboration Anixa Biosciences: A leading biotechnology company Cleveland Clinic: A renowned medical center Anixa Biosciences, a prominent biotechnology company, has joined forces with Cleveland Clinic, a renowned medical center, to present the exciting new data from a Phase 1 study of their innovative cancer vaccine.…
-
Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
NASDAQ: ALLR 1. Introduction to Allarity’s Early Phase 2 Stenoparib Data The field of oncology continues to witness groundbreaking advancements in precision medicine, with targeted therapies revolutionizing the treatment landscape for various cancers. In this context, Allarity, a leading biotechnology company, has recently released early phase 2 data showcasing the potential clinical benefit of their…
-
KALA BIO | Stock Price Up Today 43%+, Get Ready For A Move
NASDAQ: KALA Introduction to KALA BIO and its recent stock performance Investors and traders have been closely monitoring the recent surge in KALA BIO’s stock price, which has seen a remarkable 43% increase. KALA BIO, a pharmaceutical company focused on developing innovative therapies, has captured the attention of the market with its promising advancements. In…
-
NeuroSense | Reporting Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
NASDAQ: NRSN Introduction NeuroSense, a groundbreaking biopharmaceutical company, is set to release the highly anticipated topline results of its Phase 2b clinical trial for ALS (Amyotrophic Lateral Sclerosis) on December 5, 2023. This milestone event marks a significant step forward in the search for new treatment options for this devastating disease. In this article, we…
-
Soligenix | Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet’s Disease
NASDAQ: SNGX Introduction to Soligenix’s Phase 2 Clinical Trial Soligenix, a biopharmaceutical company focused on developing innovative therapies, has recently received FDA Investigational New Drug (IND) clearance for the Phase 2 clinical trial of Dusquetide in the treatment of aphthous ulcers in Behçets Disease. This clearance marks a significant milestone in the development of potential…
-
Biomea Fusion | Presenting New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
NASDAQ: BMEA BMF-219 is an investigational novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 2 diabetes STOCK & PRESS RELEASE INFO
-
BrainStorm Cell Therapeutics | Announces FDA Advisory Committee Meeting to Review NurOwn® PDUFA Target Action Date Scheduled for December 8, 2023
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced that the US FDA has granted the company a meeting to discuss the regulatory path forward for NurOwn® in ALS. The meeting, scheduled for December 6, 2023, will focus on plans for a Special Protocol Assessment (SPA) for a confirmatory Phase 3 trial in ALS. BrainStorm aims to…
-
Aptose Biosciences | Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
NASDAQ: APTO Aptose Biosciences Inc. announced that clinical data for tuspetinib has been selected for oral presentation at the 65th American Society of Hematology Annual Meeting. The presentation will include safety and efficacy data from Aptose’s ongoing APTIVATE trial of tuspetinib in relapsed/refractory acute myeloid leukemia patients. The presentation will take place on December 9,…